Affordable Access

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.

Authors
  • Stein, Stacey
  • Kortmansky, Jeremy
  • Canosa, Sandra
  • Sklar, Jeffrey
  • Swisher, Elizabeth
  • Radke, Marc
  • Ivy, Percy
  • Boerner, Scott
  • Durecki, Diane
  • Hsu, Chih-Yuan
  • LoRusso, Patricia
  • Lacy, Jill
  • Cecchini, Michael
  • Cleary, James
  • Shyr, Yu
  • Chao, Joseph
  • Uboha, Nataliya
  • Cho, May
  • Shields, Anthony
  • Pant, Shubham
  • And 3 more
Publication Date
Feb 01, 2024
Source
eScholarship - University of California
Keywords
License
Unknown
External links

Abstract

BACKGROUND: Our preclinical work revealed tumour hypoxia induces homologous recombination deficiency (HRD), increasing sensitivity to Poly (ADP-ribose) polymerase inhibitors. We aimed to induce tumour hypoxia with ramucirumab thereby sensitising tumours to olaparib. PATIENTS AND METHODS: This multi-institution single-arm Phase 1/2 trial enrolled patients with metastatic gastroesophageal adenocarcinoma refractory to ≥1 systemic treatment. In dose escalation, olaparib was evaluated at escalating dose levels with ramucirumab 8 mg/kg day 1 in 14-day cycles. The primary endpoint of Phase 1 was the recommended Phase 2 dose (RP2D), and in Phase 2 the primary endpoint was the overall response rate (ORR). RESULTS: Fifty-one patients received ramucirumab and olaparib. The RP2D was olaparib 300 mg twice daily with ramucirumab 8 mg/kg. In evaluable patients at the RP2D the ORR was 6/43 (14%) (95% CI 4.7-25.6). The median progression-free survival (PFS) was 2.8 months (95% CI 2.3-4.2) and median overall survival (OS) was 7.3 months (95% CI 5.7-13.0). Non-statistically significant improvements in PFS and OS were observed for patients with tumours with mutations in HRD genes. CONCLUSIONS: Olaparib and ramucirumab is well-tolerated with efficacy that exceeds historical controls with ramucirumab single agent for gastric cancer in a heavily pre-treated patient population.

Report this publication

Statistics

Seen <100 times